BIIB - Biogen Inc Stock Price, Fair Value and News

$180.72+0.54 (+0.30%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

BIIB Price Action

Last 7 days

-0.7%

Last 30 days

19.3%

Last 90 days

29.1%

Trailing 12 Months

12.4%

BIIB RSI Chart

BIIB Valuation

Market Cap

26.5B

Price/Earnings (Trailing)

16.48

Price/Sales (Trailing)

2.63

EV/EBITDA

9.88

Price/Free Cashflow

11.5

BIIB Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

BIIB Fundamentals

BIIB Revenue

Revenue (TTM)

10.1B

Rev. Growth (Yr)

2.79%

Rev. Growth (Qtr)

-4.19%

BIIB Earnings

Earnings (TTM)

1.6B

Earnings Growth (Yr)

20.08%

Earnings Growth (Qtr)

-26.51%

BIIB Profitability

Operating Margin

94.58%

EBT Margin

18.92%

Return on Equity

8.83%

Return on Assets

5.51%

Free Cashflow Yield

8.69%

BIIB Investor Care

Shares Dilution (1Y)

0.67%

Diluted EPS (TTM)

10.97

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	9.8B	10.0B	10.1B	0
2024	9.7B	9.7B	9.6B	9.7B
2023	10.1B	10.0B	10.0B	9.8B
2022	10.8B	10.6B	10.4B	10.2B
2021	12.6B	11.7B	11.1B	11.0B
2020	14.4B	14.5B	14.3B	13.4B
2019	13.8B	14.1B	14.2B	14.4B
2018	12.6B	12.9B	13.2B	13.5B
2017	11.5B	11.7B	11.8B	12.3B
2016	10.9B	11.2B	11.4B	11.4B
2015	10.1B	10.3B	10.6B	10.8B
2014	7.6B	8.3B	9.0B	9.7B
2013	5.6B	5.9B	6.4B	6.9B
2012	5.1B	5.3B	5.4B	5.5B
2011	4.8B	4.8B	4.9B	5.0B
2010	0	0	0	4.7B

Get all data in R, Python etc through our Historical Stock Data APIs

About Biogen Inc

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It also provides RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, immunology related diseases, neurovascular disorders, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. Biogen Inc. has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

CEO	Mr. Christopher A. Viehbacher
WEBSITE	biogen.com
SECTOR	Healthcare
INDUSTRY	Drug Manufacturers General
EMPLOYEES	8725

Biogen Inc Frequently Asked Questions

What is the ticker symbol for Biogen Inc? What does BIIB stand for in stocks?

BIIB is the stock ticker symbol of Biogen Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Biogen Inc (BIIB)?

As of Wed Dec 03 2025, market cap of Biogen Inc is 26.51 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BIIB stock?

You can check BIIB's fair value in chart for subscribers.

Is Biogen Inc a good stock to buy?

The fair value guage provides a quick view whether BIIB is over valued or under valued. Whether Biogen Inc is cheap or expensive depends on the assumptions which impact Biogen Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BIIB.

What is Biogen Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, BIIB's PE ratio (Price to Earnings) is 16.48 and Price to Sales (PS) ratio is 2.63. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BIIB PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Biogen Inc's stock?

In the past 10 years, Biogen Inc has provided -0.044 (multiply by 100 for percentage) rate of return.